Overview: CD45RO Pan T Immunohistochemistry TestIntroduction: The CD45RO Pan T Immunohistochemistry Test detects CD45RO to diagnose T-cell lymphomas, causing swelling or fever. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected T-cell lymphomas.
Other Names: CD45RO IHC Assay, T-Cell Lymphoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD45RO testing began in the 1990s with T-cell lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD45RO to diagnose T-cell lymphomas, guides treatment, and evaluates patients with swelling or fever.
Test Parameters: 1. CD45RO Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fever, or T-cell lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fever, skin rashes, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD45RO in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for T-cell lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD45RO staining suggests T-cell lymphoma, guiding chemotherapy or immunotherapy. Negative staining may require further T-cell marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD3 IHC, TCR gene rearrangement, or flow cytometry to confirm T-cell lymphoma diagnosis.
Test Limitations: Not specific to one T-cell lymphoma; other conditions may express CD45RO. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
